eViralHepatitis Revie‪w‬ eViralHepatitis Review

Take our post-test to claim CME credits.

To read a companion newsletter click here.
Why has finding a cure for hepatitis B infection been so challenging? What is it about this virus and its life cycle that makes it so different from curable HCV? In this issue, Dr. Marion Peters from the University of California San Francisco and Northwestern University explains the obstacles researchers face in their quest to tame this virus. 

See acast.com/privacy for privacy and opt-out information.

Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hepatitis C has become “curable” for >90% of those infected. But while universal HCV elimination is medically possible, this goal is compromised by certain populations who remain underscreened, undertreated, and underserved and continue to spread the virus. One such population is people who inject drugs (PWID).   

In this issue, Dr. Brianna Norton and Dr. Matthew Akiyama from the Albert Einstein College of Medicine analyze the most important data to explain how substance use impacts adherence and the risk of HCV reinfection.

See acast.com/privacy for privacy and opt-out information.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

The extrahepatic manifestations of chronic HCV can affect many different organ systems. In this eViralHepatitis Review podcast, Dr. Rajender Reddy from the University of Pennsylvania’s Perelman School of Medicine discusses clinical approaches to identifying and managing the effects of HCV infection beyond the liver.

See acast.com/privacy for privacy and opt-out information.

In this issue, Drs. Jordan Feld and Lisette Krassenburg from the Toronto Centre for Liver Disease at the University of Toronto apply the information in their recent newsletter issue to clinical practice.

Take our post-test to claim CME credits.
To read a companion newsletter click here.

See acast.com/privacy for privacy and opt-out information.

In this podcast follow-up to their recent eViralHepatitis Review newsletter issue (Vol. 6, No. 5), Dr. Mandana Khalili and Dr. Michele Tana from the University of California, San Francisco discuss how their analysis of the newer published information can impact clinical practice.

Take our post-test to claim CME credits.

To read a companion newsletter click here


See acast.com/privacy for privacy and opt-out information.

People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and impede efforts for hepatitis C eradication.

In this issue, Dr. Arthur Kim from Massachusetts General Hospital and Harvard Medical School provides a clinical perspective on identifying and overcoming the barriers that prevent PWID from effectively receiving HCV treatment.

Take our post-test to claim CME credits.

To read a companion newsletter click here.


See acast.com/privacy for privacy and opt-out information.